ArticleFrontiers in immunology2026
Genetic burden across core genes of the PI3K-AKT-mTOR pathway is associated with susceptibility to microscopic polyangiitis: a Chinese cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The PI3K-AKT-mTOR signaling pathway plays a central role in immune regulation and has been implicated in autoimmune diseases. However, the contribution of genetic variation within key components of this pathway to microscopic polyangiitis (MPA) remains incompletely understood. Methods: We conducted a genetic association study in a Chinese cohort including MPA patients and controls. Four single nucleotide polymorphisms (SNPs) within core genes of the PI3K-AKT-mTOR pathway (PIK3CA, AKT1, and MTOR) were analyzed. A cumulative genetic burden score was constructed by summing the number of risk alleles across loci. Participants were stratified into burden categories based on the distribution in controls. Logistic regression, trend analysis, and sensitivity analyses restricted to hospital-based controls were performed. Results: A high genetic burden within the PI3K-AKT-mTOR pathway was associated with increased susceptibility to MPA, with a significant linear trend across burden categories, whereas the intermediate burden group showed no significant association, suggesting a threshold-dependent effect. In sex-stratified analyses, associations appeared more evident among females, although a formal test for interaction did not indicate statistical significance. Analyses suggest a potential sex-related trend that warrants further investigation. Sensitivity analyses restricted to hospital-based controls yielded consistent results. Several common haplotypes spanning PIK3CA, AKT1, and MTOR were less frequent among patients, indicating potential protective effects. Pathway-level genetic burden was also associated with MPO-ANCA positivity. Single-variant analyses revealed generally concordant but modest effects. Conclusions: Genetic variation across selected core components of the PI3K--AKT--mTOR pathway may contribute to susceptibility to MPA. The observed patterns, including potential sex-related differences, should be interpreted cautiously and require validation in larger and independent cohorts. These findings highlight a potential pathway-level genetic architecture underlying MPA susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.